Humana (HUM) Expected to Announce Earnings on Wednesday

Humana (NYSE:HUM - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $6.32 per share and revenue of $31.85 billion for the quarter.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.07 by $1.51. The firm had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $7.23 earnings per share. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $13 EPS for the next fiscal year.

Humana Stock Up 3.9%

HUM traded up $9.01 during trading on Friday, hitting $238.22. The company had a trading volume of 1,569,145 shares, compared to its average volume of 1,505,668. The company has a market cap of $28.75 billion, a PE ratio of 16.85, a P/E/G ratio of 1.57 and a beta of 0.44. Humana has a 1-year low of $206.87 and a 1-year high of $406.09. The business has a 50-day moving average of $234.56 and a 200-day moving average of $256.27. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Hedge Funds Weigh In On Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 798 shares of the insurance provider's stock, valued at approximately $202,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

A number of analysts have weighed in on HUM shares. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a report on Sunday, July 20th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Barclays set a $268.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Truist Financial dropped their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Finally, Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Sixteen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of "Hold" and an average price target of $282.43.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.